Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV study tracks kids treated early for clues to remission

NCT ID NCT05154513

Knowledge-focused Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 163 children with HIV who started treatment within 12 weeks of birth. Researchers measured their growth, immune health, and virus levels over about seven years. No new treatment was given; the goal was to gather long-term data to help design future studies aiming for HIV remission or cure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could provide crucial data to guide future research aimed at HIV remission or cure in children.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly test any new therapy. The results may not apply to all children with HIV.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

163 people

The number who actually took part.

Started

Feb 2022

Finished

Jul 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Up to approximately 250 children living with HIV who received early treatment in IMPAACT network studies or other research studies sponsored by the US National Institutes of Health (NIH)

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participated in one of the parent studies * Confirmed HIV-1 infection based on documented nucleic acid testing of two blood samples collected at different time points * Received early treatment for HIV-1 infection, defined as treatment with at least three ARV agents from at least two classes of ART, initiated within 12 weeks of birth * Based on parent or guardian report at entry, child is expected to be available for at least 24 months of follow-up * Parent or guardian is willing and able to provide written informed consent for child's study participation and, when applicable per institutional review board/ethics committee (IRB/EC) policies and procedures, child is willing and able to provide written assent for study participation Exclusion Criteria: * Has any documented or suspected clinically significant medical condition or any other condition that, in the opinion of the site investigator, would make participation in the study unsafe or otherwise interfere with completing study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV infection

Contacts and locations

Locations

  • 30300, Umlazi Clinical Research Site

    Durban, South Africa

  • 31798, Baylor-Uganda Clinical Research Site

    Kampala, Uganda

  • 5030, Emory University School of Medicine Clinical Research Site

    Atlanta, Georgia, 30322, United States

  • 5055, South Florida CDTC Fort Lauderdale Clinical Research Site

    Fort Lauderdale, Florida, 33316, United States

  • 5071, Instituto de Puericultura e Pediatria Martagao Gesteira Clinical Research Site

    Rio de Janeiro, Brazil

  • 5121, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center Kericho Clinical Research Site

    Kericho, Kenya

  • 5128, Texas Children's Hospital Clinical Research Site

    Houston, Texas, 77030, United States

  • 8051, Wits RHI Shandukani Research Centre Clinical Research Site

    Johannesburg, South Africa

  • Chiang Rai Regional Hospital (5116)

    Chiang Rai, Thailand

  • College of Med. JHU CRS (30301)

    Blantyre, Malawi

  • David Geffen School of Medicine at UCLA (CRS 5112)

    Los Angeles, California, 90095, United States

  • Family Clinical Research Unit (FAM-CRU) CRS (8950)

    Tygerberg Hills, South Africa

  • Gaborone CRS 12701

    Gaborone, Botswana

  • Harare Family Care (31890)

    Harare, Zimbabwe

  • Hospital Geral De Nova Igaucu (5097)

    Rio de Janeiro, Brazil

  • Hospital dos Servidores Rio de Janeiro

    Rio de Janeiro, Brazil

  • Kilimanjaro Christian Medical Centre (5118)

    Moshi, Tanzania

  • Les Centres GHESKIO (30022)

    Port-au-Prince, Haiti

  • Molepolole Prevention/Treatment Trials CRS 12702

    Molepolole, Botswana

  • Ribeirao Preto Medical School, University of Sao Paulo (5074)

    São Paulo, Brazil

  • School of Medicine, University of Minas Gerais - FUNDEP (5073)

    Belo Horizonte, Brazil

  • Seke North CRS 30306

    Chitungwiza, Zimbabwe

  • Siriraj Hospital Mahidol University CRS (5115)

    Bangkok, Ratchathewi, 10700, Thailand

  • Soweto IMPAACT CRS (8052)

    Johannesburg, Gauteng, South Africa

  • St. Mary's CRS 30303

    Chitungwiza, Zimbabwe

  • Univ of Miami Pediatric/Perinatal HIV/AIDS (5127)

    Miami, Florida, 33136, United States

  • University of Colorado (5052)

    Aurora, Colorado, 80045, United States

  • University of North Carolina Lilongwe (12001)

    Lilongwe, Malawi

More trials for these conditions

Other studies related to the condition(s) this trial covers.